Ada Trindade de Almeida1, Jean Carruthers, Sue Ellen Cox, Mitchel P Goldman, Sarah Wheeler, Conor J Gallagher. 1. *Hospital Do Servidor Publico Municipal, Sao Paulo, Brazil; †Carruthers Clinical Research, Vancouver, British Columbia, Canada; ‡Aesthetic Solutions, Chapel Hill, North Carolina; §Goldman, Butterwick, Fitzpatrick, Groff and Fabi: Cosmetic Laser Dermatology, San Diego, California; ‖Allergan, Inc., Irvine, California.
Abstract
BACKGROUND: Despite extensive clinical experience with onabotulinumtoxinA, few data exist on patient satisfaction or safety with continuous treatment. OBJECTIVE: This international multicenter study evaluated patient satisfaction and safety with long-term continuous facial aesthetic treatment with onabotulinumtoxinA. METHODS: Retrospective chart review with a cross-sectional design was used to assess onabotulinumtoxinA treatment, including dosing, concomitant facial aesthetic medications and procedures, and adverse events (AEs). Validated Facial Line Satisfaction Questionnaire, Self-Perception of Age measure, and Facial Line Outcomes questionnaire instruments, and a de novo questionnaire were used to determine patient satisfaction. RESULTS: A total of 207 patients consisted of the intent-to-treat population, with 194 in the per protocol analyses. Patients received a total of 4,402 glabellar treatments over a mean of 9.1 years, with a mean dose of 21.6 U per treatment. Overall, 92.3% of patients were mostly or very satisfied. Among the 89.7% of patients who reported looking younger, the mean perceived age was 6.9 years younger. Documented AEs were infrequent, mostly mild in severity, and declined in frequency over time. LIMITATIONS: This population was self-selecting as they chose to continue treatment for 5 or more years to be eligible. CONCLUSION: Continuous treatment with onabotulinumtoxinA for a mean of 9.1 years was associated with very high patient satisfaction.
BACKGROUND: Despite extensive clinical experience with onabotulinumtoxinA, few data exist on patient satisfaction or safety with continuous treatment. OBJECTIVE: This international multicenter study evaluated patient satisfaction and safety with long-term continuous facial aesthetic treatment with onabotulinumtoxinA. METHODS: Retrospective chart review with a cross-sectional design was used to assess onabotulinumtoxinA treatment, including dosing, concomitant facial aesthetic medications and procedures, and adverse events (AEs). Validated Facial Line Satisfaction Questionnaire, Self-Perception of Age measure, and Facial Line Outcomes questionnaire instruments, and a de novo questionnaire were used to determine patient satisfaction. RESULTS: A total of 207 patients consisted of the intent-to-treat population, with 194 in the per protocol analyses. Patients received a total of 4,402 glabellar treatments over a mean of 9.1 years, with a mean dose of 21.6 U per treatment. Overall, 92.3% of patients were mostly or very satisfied. Among the 89.7% of patients who reported looking younger, the mean perceived age was 6.9 years younger. Documented AEs were infrequent, mostly mild in severity, and declined in frequency over time. LIMITATIONS: This population was self-selecting as they chose to continue treatment for 5 or more years to be eligible. CONCLUSION: Continuous treatment with onabotulinumtoxinA for a mean of 9.1 years was associated with very high patient satisfaction.
Authors: Hema Sundaram; Massimo Signorini; Steven Liew; Ada R Trindade de Almeida; Yan Wu; André Vieira Braz; Steven Fagien; Greg J Goodman; Gary Monheit; Hervé Raspaldo Journal: Plast Reconstr Surg Date: 2016-03 Impact factor: 4.730
Authors: Joel L Cohen; Alexander Rivkin; Steven Dayan; Ava Shamban; W Philip Werschler; Craig F Teller; Michael S Kaminer; Jonathan M Sykes; Susan H Weinkle; Julie K Garcia Journal: Aesthet Surg J Date: 2022-01-12 Impact factor: 4.283